Lasa Supergenerics Limited

NSE LASA.NS

Lasa Supergenerics Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD -231.62 K

Lasa Supergenerics Limited Net Cash Used Provided By Financing Activities is USD -231.62 K for the year ending March 31, 2024, a 54.25% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Lasa Supergenerics Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD -506.22 K, a -9,437.81% change year over year.
Lasa Supergenerics Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD -5.31 K, a 99.89% change year over year.
Lasa Supergenerics Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD -4.98 M, a -280.78% change year over year.
Lasa Supergenerics Limited Net Cash Used Provided By Financing Activities for the year ending March 31, 2020 was USD -1.31 M, a 72.80% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NSE: LASA.NS

Lasa Supergenerics Limited

CEO	Dr. Omkar Pravin Herlekar
IPO Date	Sept. 21, 2017
Location	India
Headquarters	No. 506 & 507, Midas Sahar Plaza
Employees	77
Sector	Consumers Staples
Industries Pet Food Agriculture Biotechnology Cleaning Supplies Cosmetics Dairy & Milk Personal Care Pharmaceuticals

Description

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents for therapeutic use. The company also exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Mumbai, India.

Key trends

Past 5 years